Dimensional Fund Advisors LP Purchases 22,621 Shares of Boston Scientific Co. (NYSE:BSX)

Dimensional Fund Advisors LP raised its stake in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 0.5% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 4,914,442 shares of the medical equipment provider's stock after buying an additional 22,621 shares during the quarter. Dimensional Fund Advisors LP owned about 0.33% of Boston Scientific worth $438,979,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Parnassus Investments LLC boosted its position in shares of Boston Scientific by 0.7% in the fourth quarter. Parnassus Investments LLC now owns 14,861 shares of the medical equipment provider's stock worth $1,327,000 after acquiring an additional 97 shares during the last quarter. Evergreen Capital Management LLC lifted its holdings in Boston Scientific by 1.7% in the 4th quarter. Evergreen Capital Management LLC now owns 6,331 shares of the medical equipment provider's stock worth $565,000 after buying an additional 106 shares in the last quarter. PDS Planning Inc lifted its stake in shares of Boston Scientific by 1.5% in the fourth quarter. PDS Planning Inc now owns 7,474 shares of the medical equipment provider's stock worth $668,000 after acquiring an additional 113 shares in the last quarter. Adero Partners LLC boosted its stake in shares of Boston Scientific by 3.3% during the 4th quarter. Adero Partners LLC now owns 3,737 shares of the medical equipment provider's stock valued at $334,000 after buying an additional 120 shares during the last quarter. Finally, Grove Bank & Trust boosted its stake in Boston Scientific by 4.4% during the 4th quarter. Grove Bank & Trust now owns 2,923 shares of the medical equipment provider's stock valued at $261,000 after acquiring an additional 122 shares during the last quarter. Hedge funds and other institutional investors own 89.07% of the company's stock.

Boston Scientific Stock Up 2.2 %

NYSE:BSX traded up $2.21 during trading hours on Thursday, reaching $101.13. The company's stock had a trading volume of 8,984,286 shares, compared to its average volume of 8,002,299. Boston Scientific Co. has a one year low of $70.97 and a one year high of $107.17. The business's 50-day moving average is $98.85 and its 200-day moving average is $94.58. The company has a market cap of $149.58 billion, a price-to-earnings ratio of 80.90, a price-to-earnings-growth ratio of 2.79 and a beta of 0.73. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.08 and a quick ratio of 1.02.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings data on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping analysts' consensus estimates of $0.67 by $0.08. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. The business had revenue of $4.66 billion during the quarter, compared to analysts' expectations of $4.57 billion. Equities research analysts predict that Boston Scientific Co. will post 2.85 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Barclays raised their price objective on Boston Scientific from $111.00 to $118.00 and gave the stock an "overweight" rating in a research note on Monday, February 10th. Needham & Company LLC increased their target price on shares of Boston Scientific from $113.00 to $115.00 and gave the company a "buy" rating in a research report on Thursday. Wells Fargo & Company lifted their price target on Boston Scientific from $100.00 to $118.00 and gave the company an "overweight" rating in a research report on Thursday, February 6th. Robert W. Baird lifted their price objective on shares of Boston Scientific from $115.00 to $120.00 and gave the stock an "outperform" rating in a research note on Thursday. Finally, Citigroup boosted their target price on Boston Scientific from $107.00 to $122.00 and gave the stock a "buy" rating in a research report on Thursday, February 6th. One analyst has rated the stock with a hold rating, twenty-two have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $112.87.

Insiders Place Their Bets

In other Boston Scientific news, SVP Vance R. Brown sold 4,826 shares of the business's stock in a transaction on Monday, April 21st. The shares were sold at an average price of $95.09, for a total value of $458,904.34. Following the sale, the senior vice president now owns 36,193 shares of the company's stock, valued at $3,441,592.37. The trade was a 11.77 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Arthur C. Butcher sold 17,313 shares of the company's stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $101.80, for a total transaction of $1,762,463.40. Following the completion of the sale, the executive vice president now directly owns 5,502 shares in the company, valued at approximately $560,103.60. The trade was a 75.88 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 138,009 shares of company stock valued at $14,407,381 in the last three months. Company insiders own 0.50% of the company's stock.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.